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Study Objectives: Obstructive sleep apnea (OSA) has been
associated with psychiatric pathology. Psychiatric comorbidity
in OSA may affect patient quality of life and adherence to
CPAP. A focused evaluation of OSA in highly selected groups
of primarily psychiatric patients may provide further insights
into the factors contributing to comorbidity of OSA and
psychopathology. The goal of this study is to examine the
prevalence and treatment of OSA in psychiatric populations.
Methods: A systematic review following the PRISMA
guidelines was conducted to determine the prevalence of
OSA in schizophrenia and other psychotic disorders, mood
disorders, and anxiety disorders, and to examine potential
interventions. The PubMed, EMBASE, and PsycINFO
databases were searched (last search April 26, 2014) using
keywords based on the ICD-9-CM coding for OSA and the
DSM-IV-TR diagnostic groups.
Results: The search retrieved 48 records concerning studies of
OSA in the selected disorders. The prevalence studies indicate

that there may be an increased prevalence of OSA in individuals
with major depressive disorder (MDD) and posttraumatic stress
disorder (PTSD), despite considerable heterogeneity and a
high risk of bias. There was insufficient evidence to support
increased OSA in schizophrenia and psychotic disorders,
bipolar and related disorders, and anxiety disorders other than
PTSD. Studies of treatment of OSA indicate an improvement
in both OSA and psychiatric symptoms. CPAP adherence was
reduced in veterans with PTSD.
Conclusions: OSA prevalence may be increased in MDD
and PTSD. In individuals with OSA and psychiatric illness,
treatment of both disorders should be considered for optimal
treatment outcomes.
Keywords: obstructive sleep apnea, psychiatry, PTSD,
depression, comorbidity
Citation: Gupta MA, Simpson FC. Obstructive sleep apnea
and psychiatric disorders: a systematic review. J Clin Sleep
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O

bstructive sleep apnea (OSA) is a sleep-related breathing disorder characterized by repeated episodes of upper airway obstruction during sleep.1 According to a major
US study of OSA diagnosed by polysomnography (PSG), the
prevalence of OSA, as defi ned by an apnea-hypopnea index
(AHI) ≥ 5 and without inclusion of a daytime sleepiness criterion, was reported as 24% for men and 9% for women under
the age of 65 years; addition of a daytime sleepiness criterion
reduced these estimates to 4% for men and 2% for women.1,2
OSA is commonly associated with metabolic syndrome including comorbid obesity, hypertension, and diabetes.1 Upper airway obstruction may present as apneas, hypopneas, or
respiratory effort-related arousals (RERAs), resulting in oxygen desaturation, repeated arousals and sleep fragmentation.1
Recently, there has been an increase in reports of comorbidity
of OSA with psychological/psychiatric symptoms. Psychiatric comorbidity in OSA has been reported to adversely affect
the quality of life of OSA patients and adherence to CPAP
therapy.3–5
Psychological symptoms such as depression and anxiety
are commonly reported in adults with OSA; however, the relationship between OSA and full psychiatric syndromes is less
clear. Global prevalence studies and reviews have suggested
that there are elevated rates of psychological symptoms in individuals with OSA.6–16 These studies are limited in their ability

to confirm psychiatric diagnoses, as psychiatric symptoms are
commonly evaluated using self- or clinician rated psychiatric
severity scales, not a diagnostic evaluation by an experienced
clinician. Sleep symptoms may also artificially elevate patient
scores on psychiatric scales. Popular scales, such as the Beck
Depression Inventory (BDI), Profile of Mood States (POMS),
and Minnesota Multiphasic Personality Inventory (MMPI),
have questions relating to sleep symptoms such as insomnia
and fatigue that are common to both OSA and psychiatric conditions.17–19 Studies that have evaluated the prevalence of OSA
in the highly selected groups of psychiatric populations may
provide additional insight into the factors contributing to the
comorbidity of OSA and psychopathology.
Our objectives were (1) to perform a comprehensive evaluation of the prevalence of OSA in the major psychiatric disorders including schizophrenia and other psychotic disorders,
mood disorders, and anxiety disorders; and (2) to perform a
narrative evaluation of interventions for the treatment of OSA
in individuals with schizophrenia and other psychotic disorders, mood disorders, and anxiety disorders.

METHODS
The methodology for the systematic review was carried out
according to the PRISMA guidelines.20
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the ICD-9 codes for schizophrenia and other psychotic disorders, mood disorders, and anxiety disorders. These diagnostic
groups coincided with the respective DSM-IV-TR categories for
these disorders.21,22 The full search strategy for PubMed can be
viewed in Table S1 (Appendix 1). Additional articles were identified by hand search of the reference sections of relevant papers.

Figure 1—Flow diagram of study selection.

Study Selection

Full text articles were evaluated for inclusion by 2 independent reviewers (FS and KK), and disagreements were resolved
by discussion to reach a consensus. Study populations discussed in multiple articles were grouped under a single study
identifier by the final report (i.e., preliminary conference abstracts would be found under the identifier for the final published journal article) (Appendix 2).
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Data Extraction

Data extraction was conducted independently by FS using
a standard form for prevalence and intervention studies. The
data collected for prevalence studies included the study identifier, sample size for any groups, gender, characteristics of the
study population, the mean age, mean BMI, psychiatric medications used, psychiatric diagnostic criteria, and OSA diagnostic criteria. The data collected for intervention studies included
the study identifier, sample size for any groups, gender, characteristics of the study population, psychiatric medications
used, psychiatric diagnostic criteria, OSA diagnostic criteria,
type of intervention, duration of intervention, study outcome
measures, and results of the outcome measures. The authors
of studies with missing or incomplete data were contacted via
email to request additional data. In several large epidemiological studies of concurrent diagnoses of OSA and psychiatric disorders, the scores of the prevalence of psychiatric disorders in
OSA were converted into scores for the prevalence of OSA in
psychiatric disorders where the data permitted conversion.24–26

Eligibility Criteria

Risk of Bias

The inclusion criteria are: subjects with clinically diagnosed
schizophrenia and other psychotic disorders, mood disorders,
and anxiety disorders and an OSA diagnosis conducted using
PSG. A clinical diagnosis for a psychiatric disorder must have
been established by a clinician using an interview or clinicianrated scale. Psychiatric disorders were classified based on the
system used in the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition, text revision (DSM-IV-TR), although
studies using prior editions were also acceptable.21 This diagnosis could be determined prospectively from the patient, through
a chart review, or through the use of insurance coding using
the International Classification of Diseases, Ninth Revision
(ICD-9) or 10th Revision (ICD-10).22,23 The criteria for OSA required a PSG (single or split-night) meeting the International
Classification of Sleep Disorders, 2nd edition (ICSD-2) criteria
for OSA with AHI ≥ 5 events/h or the respiratory disturbance
index (RDI) equivalent.1 The exclusion criteria were: non-English language articles, review articles, and animal studies.

The quality of the included studies was evaluated by 2 independent reviewers (FS and KK) using the Hoy tool for assessing risk of bias (RoB) in prevalence studies and the Cochrane
Risk of Bias tool for interventions.27,28 Case reports were not
assessed for RoB. The inter-rater reliability between the reviewers’ RoB assessments was assessed using Cohen’s κ in
IBM SPSS Statistics 20 (Armonk, NY).29

RESULTS
Included Studies

Our search identified 974 individual manuscripts relating to
psychiatric disorders in subjects diagnosed with OSA. Of these,
48 records containing 44 studies concerned subjects with clinically diagnosed schizophrenia and other psychotic disorders,
mood disorders, and anxiety disorders, who were evaluated by
polysomnography for OSA (Figure 1; Table S2, Appendix 1).

Information and Sources

Study Design

The search was conducted in PubMed (including MEDLINE),
EMBASE (from 1974) via OVID, and PsycINFO (from 1806)
via OVID up to April 26, 2014. The search terms were based on
Journal of Clinical Sleep Medicine, Vol. 11, No. 2, 2015

The included studies for prevalence were categorized based
on whether they were population-based samples, clinical or
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Table 1—Summary of findings: prevalence.
Psychiatric Disorder
Schizophrenia
Schizoaffective Disorder
Schizophrenia and Psychotic Disorders
BD-I and BD-II
MDD
Anxiety Disorders
PTSD

Clinic-Based Prevalence
Number of
Range
Median
Studies
0.7– 47.8%
–
224,30
3.2%
–
130
48%
–
131
2.9–69%
19.8%
424,30,32–34
0–66%
48.1%
824,26,30,32,35–38
47.5% *
–
126
24,26,40–44
1.3–83%
42.7%
7

Population-Based Prevalence
Number of
Range
Median
Studies
–
–
–
–
–
–
4.52%
–
125
6.9%
–
125
7.4–44%
–
225,39
6.4–58.1% **
–
225,39
46.4–50%
–
225,39
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* Includes PTSD. ** Excludes PTSD. (–), not reported; BD-I, Bipolar Disorder Type I; BD-II, Bipolar Disorder Type II; MDD, major depressive disorder;
PTSD, posttraumatic stress disorder.

schizoaffective disorder (Table 1; Table S5, Appendix 2).30
Levine found that the prevalence of OSA was 3.2% in 93 subjects with schizoaffective disorder.
Pooled Schizophrenia and Psychotic Disorders: There
has been one clinic-based and one population-based study on
pooled schizophrenia and other psychotic disorders.25,31 The
clinic-based population showed a 48% prevalence of OSA
in mixed schizophrenia and schizoaffective disorder participants.31 The population-based study conducted using the
United States Veterans Health Administration (VHA) records
reported an OSA prevalence in pooled schizophrenia and psychotic disorders of 4.52%.25

inpatient samples. Overall, most prevalence studies were based
on sleep clinic referrals or inpatient psychiatric populations.
Due to the heterogeneous nature of the study populations,
no pooled estimates of population prevalence were possible
(Appendix 3, Section A). The inter-rater reliability score for
RoB for prevalence studies was 0.871.
The search for intervention studies resulted in a combination of case reports and prospective and retrospective studies.
These studies also presented a wide variety of interventions for
OSA in subjects with psychiatric disorders, including CPAP,
armodafinil, and uvulopalatopharyngoplasty (UPPP). RoB
was only assessed for prospective and retrospective studies
meeting the inclusion criteria, due to the obvious sample size
bias of a report on a single individual (Appendix 3, Section B).
The inter-rater reliability score for RoB for intervention studies
was 0.828. Intervention data, categorized by psychiatric diagnosis, are subsequently presented.

M ood D isorders

Bipolar I and II Disorder: There were 5 studies that reported the prevalence of OSA in bipolar I and II disorders (BD);
4 clinical studies and a single population-based study (Table 1;
Table S6, Appendix 2).24,25,30,32–34 In the clinic-based studies,
the prevalence of OSA ranged from 2.9% to 69%. All 4 studies were at a high risk of selection bias. The range of prevalence may be related to the clinical population studied. Hattori
reported the highest prevalence of 69% in a population of individuals with BD requiring a depression score on the HAMD ≥ 10 and clinical signs of OSA.32 This study has the greatest
selection bias for OSA due to the requirement for active depressive symptoms and clinical signs of OSA. The lowest prevalence reported was 2.9% by Levine in a study of consecutive
psychiatric patients at a state hospital where no pre-existing
sleep symptoms were required for inclusion.30 The populations
of psychiatric inpatient sleep clinic referrals and consecutive
BD patients showed moderate prevalence of 18.5% and 21%,
respectively.24,33 In Winkelman, there is a selection bias for psychiatric inpatients with sleep disturbance that is not specific to
OSA and a reduced diagnostic threshold of an RDI > 10.24 In
Kelly, the study participants are consecutive outpatients, but the
criteria for OSA are more stringent; requiring presenting EDS
for diagnosis if the AHI is > 5 and < 15 events per hour or an
AHI ≥ 15.33,34 In the population-based study, the reported rate of
OSA in BD was 6.94% in the VHA database.25
Major Depressive Disorder: Ten studies on the prevalence
of OSA in individuals with major depressive disorder (MDD)
were identified—8 clinic-based studies and 2 population-based

Subjects
Excluded Studies
There were 82 excluded studies based on the full text review
(Figure 1; Table S3, Appendix 1). The reasons for exclusion
are presented in Table S4 (Appendix 1). The most common
reason for exclusion was the lack of a clinical psychiatric diagnosis, followed by lack of diagnostic PSG.
Prevalence
S chizophrenia and Psychotic D isorders

Schizophrenia: There have been 2 clinic-based studies conducted on the prevalence of OSA in schizophrenia
(Table 1; Table S5, Appendix 2).24,30 The clinic-based studies reported a prevalence range of 0.73% to 48.0%, and both
studies had high risk of selection bias. The discrepancy between the reported prevalence is likely due to Levine reporting prevalence in consecutive psychiatric inpatients, while
Winkelman reported prevalence in psychiatric patients with
sleep clinic referrals, which is a substantial bias towards a
higher prevalence of OSA.24,30
Schizoaffective Disorder: A single clinic-based prevalence study has been conducted on the prevalence of OSA in
167
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Table 2—Summary of findings: interventions.45–74
Disorders

Case Reports

Single-Assignment Trials or
Retrospective Reviews

Randomized Controlled Trials

Schizophrenia and
Psychotic Disorders

CPAP with psychopharmaceuticals
improved psychosis: 9 cases46–55

–

–

–

–

UPPP decreased EDS and current
depression: 1 study60

Armodafinil 200 mg/day was superior
to placebo at reducing EDS: 1 study64–67

AT resolved OSA: 1 case45
BD: Manic Episodes

CPAP induced manic episode:
4 cases55,56,58
ECT and BiPAP resolved mania and
psychosis: 1 case57
Topiramate 100 mg/day reduced
apneas and snoring: 1 case59

MDD

Panic Disorder
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PTSD

–

CPAP reduced depression severity. In
two studies CPAP also decreased EDS:
3 studies61–63

–

–

CPAP vs. Sham CPAP. CPAP reduced
panic attacks, symptom severity and
alprazolam use: 1 study68

CPAP reduced symptoms of PTSD:
2 cases73,74

CPAP compliance was reduced
in participants with PTSD. CPAP
compliance reduced nightmare
frequency: 4 studies69–72

–

(–), not reported; AT, adenotonsillectomy; BD, bipolar disorder; CPAP, continuous positive airway pressure; EDS, excessive daytime sleepiness; MDD, major
depressive disorder; PSTD, posttraumatic stress disorder; RCT, randomized controlled trial; SAT, single-assignment trial; UPPP, uvulopalatopharyngoplasty.

studies (Table 1; Table S7, Appendix 2).24–26,30,32,35–39 The
clinic-based studies range in prevalence from 0% to 66%.
Seven studies were at high risk of selection bias, and one
study was at moderate risk of selection bias. The lowest prevalence of 0% was found by Levine in a sample of consecutive
psychiatric inpatients without sleep symptoms.30 The highest prevalence of 66% was found by Carney in subjects with
comorbid coronary heart disease who have an increased risk
for both depression secondary to CHD and for OSA due to
pathophysiologic factors underlying CHD including obesity.36
High selection bias for pre-existing sleep symptoms was present for sleep disturbance in Winkelman (12%) and insomnia in
Ong (39%).24,37 A specific depression severity was required for
inclusion for the studies of Deldin (53%), Hattori (53%), and
Summers (46.7%).32,35,38 The final study, Mysliwiec, was conducted in a military population where routine PSG is a postcombat requirement, which may increase the reporting bias
for OSA.26 Overall, 6 of the 8 clinic-based samples reported
an elevated rate of OSA in MDD. In population based studies,
Sharafkhaneh reported a prevalence of 7.4% in the VHA vs.
44% for a community population sample in Hrubos-Strom.25,39
This difference may be affected by sample size, as the final
sample of MDD patients in Hrubos-Strom was 36 subjects,
compared to 358,817 in Sharafkhaneh.
Dysthymia: A single study was identified that reported the
prevalence of OSA in dysthymia. Hrubos-Strom 2012 reported
that 3 of 5 (60%) individuals with dysthymia had a clinical
diagnosis of OSA; however, the sample size and moderate RoB
limit the generalizability of this data.39
Journal of Clinical Sleep Medicine, Vol. 11, No. 2, 2015

A nxiety D isorders

Three studies reported the prevalence of pooled anxiety
diagnoses (Table 1; Table S8, Appendix 2).25,26,39 The clinicbased sample in Mysliwiec reported a prevalence of anxiety
disorders excluding PTSD as 47.5% for their time interval.26
This study was at a moderate RoB, as it included all diagnostic
PSG performed on postcombats veterans as a routine measure.
Hrubos-Strom reported a rate in current anxiety disorders including PTSD as 58.1% in a moderate RoB community survey-based sample.39 This study is also the only study to report
prevalence for individual anxiety disorders other than PTSD
(Table 1; Table S8, Appendix 2). The prevalence of OSA was
58.8% in panic disorder (n = 17), 100% in agoraphobia without
panic disorder (n = 2), 53.8% in social phobia (n = 13), 40%
in obsessive compulsive disorder (n = 5), and 57.1% in generalized anxiety disorder (n = 14), respectively. However, the
small sample sizes limit the generalizability of these results.
The population-based study Sharafkhaneh reported an OSA
prevalence of 6.4% in anxiety disorders including PTSD in
the VHA.25 The anxiety disorders represented the most heterogeneous group, as some studies pooled all anxiety disorders
under one grouping while others either excluded PTSD or reported on individual diagnoses.
Posttraumatic Stress Disorder (PTSD): There were 9
studies that reported the prevalence of OSA in PTSD; 7 studies were clinic-based and 2 studies were population-based
(Table 1; Table S9, Appendix 2).24–26,39–44 The clinic-based
studies reported a prevalence range of 0.7% to 83%.24,26,40–44
Six studies were considered to have high risk of selection bias,
168
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and one had a moderate risk of selection bias due to population
sample, sleep symptom requirements, and/or PTSD severity.
Kinoshita (83%) and Yesavage (69%) required participants to
be male, aged ≥ 55 with a CAPS score ≥ 40, each of which
acts as a selection bias towards increased OSA prevalence.41,42
Two studies by Mysliwiec26,43 examined postcombat PSG in
military personnel, and the second of these43 required a PTSD
Checklist Military Version score ≥ 50, both of which act as
selection biases. The van Liempt study also included male veterans with a CAPS score > 50.44 The 2 civilian clinic samples
reported the lowest prevalence of OSA in PTSD. Winkelman
included consecutive psychiatric inpatients with sleep disturbances as selection bias. Krakow recruited crime victims with
nightmares and insomnia with a PTSD severity requirement
of Posttraumatic Stress Diagnostic Scale (PSDS) score ≥ 11.40
The population-based studies reported a prevalence range of
46.4% to 50%.25,39 These studies were at a low and moderate
RoB, respectively. Six of the 9 studies were conducted in past
and present military populations, which reported a range of
42.7% to 50% for both classes of study.25,26,41–44 Civilian populations had the greatest discrepancy in prevalence rates from
0.7% to 50%.24,39,40

6.6/h. There was no weight change observed during the course
of treatment.
The systematic review did not identify any clinical trials
which evaluated the impact of treating OSA on symptoms of
BD. The 4 case studies on emergent mania during treatment
with CPAP may not be indicative of the overall effect of treating OSA in individuals with BD, as there is a tendency to publish case reports on exceptional circumstances, not successful
routine treatment. The successful use of topiramate, which
falls outside the parameters of routine treatment for OSA, further illustrates the high likelihood that publication bias is present for OSA and BD. Randomized controlled trials (RCTs) are
required to determine the impact of treating OSA on symptoms of BD.
Major Depressive Disorder: Five intervention studies
were included concerning the treatment of subjects with depressive disorders and OSA (Table 2; Table S12, Appendix
2).60–67 A single study examined the effect UPPP on patients
with a current major depressive episode (MDE).60 At 6-month
follow-up, the rate of current MDE had decreased to 10% from
34%, and hypersomnia decreased from 98% to 6%. Three
studies examined the effect of CPAP in OSA in individuals
with MDD. In all studies, CPAP reduced the severity of depression measured by the BDI and the Hamilton Rating Scale
for Depression (HAM-D). Habukawa demonstrated that the
decrease in BDI and HAM-D correlated with decreases in the
Epworth Sleepiness Scale (ESS) score.62 El-Sherbini reported
resolution of MDD for 6 of 11 subjects with Structured Clinical Interview for DSM-IV Disorders diagnosed MDD.63 The
final study examined the effect of armodafinil in individuals
with MDD or dysthymic disorder on stable antidepressant regimens and a stable CPAP regimen.64–67 The study showed that
armodafinil resulted in minimal Clinical Global Impression of
Change improvement over placebo and a significant decrease
in ESS scores.
There is significant publication and clinical trial design bias
present in the studies conducted in individuals with MDD and
OSA. UPPP has only been evaluated in a single-open label
trial which limits the generalizability of the conclusions of
this study. The 3 trials on CPAP were also single-assignment,
open-label trials that each had different inclusion criteria for
OSA. In addition, Habukawa was the sole study that required
concurrent antidepressant treatment. For all 4 single arm trials,
the lack of comparison to a sham-control group or alternate
active therapy makes it difficult to determine if the depressive
symptoms respond to the specific treatment or to placebo effect. The fifth trial, Krystal, fulfills the criteria for a gold standard RCT; however, armodafinil is intended to treat symptoms
of EDS secondary to OSA. This therapy may be of benefit to
individuals who present with EDS and OSA, but it is not indicative of the effect of treating the primary OSA on symptoms of
MDD. RCTs are required to determine the impact of treating
OSA on symptoms of MDD.

Interventions
S chizophrenia and Psychotic D isorders

Ten case studies were identified concerning the treatment
of a spectrum of schizophrenia and psychotic disorders in
individuals with undiagnosed OSA (Table 2; Table S10,
Appendix 2).45–54 Case reports concerned men in 83.3% of included studies. The most common intervention for OSA was
CPAP in combination with existing psychiatric medications.
In all but one case, CPAP resulted in improvement in excessive
daytime sleepiness and negative psychotic symptoms. Chiner
was the sole report of an acute psychotic episode induced by
CPAP therapy.47 Lee was the sole case report on adenotonsillectomy resolving a subject’s psychosis and OSA; this patient
also had temporal lobe epilepsy, which could have been the basis for the psychotic symptoms.45 There are no available clinical trials evaluating the impact of the treatment of OSA on the
presentation of symptoms of schizophrenia.
M ood D isorders

Bipolar Disorder: Four case reports on the relationship between CPAP and manic episodes have been reported for individuals with BD (Table 2; Table S11, Appendix 2).55–58 In
4 cases, male subjects were admitted for depressive episodes
where OSA was diagnosed after observation and PSG.55,56,58
The subjects developed mania after 2–4 weeks of CPAP use.
These patients required mood stabilizers or atypical antipsychotics to stabilize the manic episode, and it is clear that only
2 subjects continued with long-term CPAP use. The fifth case
report concerns a female subject with a mixed manic and psychotic episode, who was treated with 12 sessions of ECT followed by CPAP and psychiatric drugs.57
An additional case study by Weber examined the effect of
adding 100 mg/day of topiramate to the existing drug regimen
of a 50-year-old man with BD.59 The topiramate resulted in a
reduction of snoring and a decrease in apneas from 20.0/h to

A nxiety D isorders

Panic Disorder: A randomized, crossover, sham-controlled
study of CPAP was conducted in individuals with panic disorder (Table 2).68 In Takaesu, participants were randomized to 4
weeks CPAP, 4 weeks off, and 4 weeks of sham CPAP, or the
169

Journal of Clinical Sleep Medicine, Vol. 11, No. 2, 2015

Downloaded from jcsm.aasm.org by 207.136.114.76 on June 22, 2022. For personal use only. No other uses without permission.
Copyright 2022 American Academy of Sleep Medicine. All rights reserved.

MA Gupta and FC Simpson

same regimen with CPAP and sham CPAP reversed. At followup, individuals who underwent CPAP therapy showed reduction in panic attacks, symptom severity, and alprazolam use
when compared to the sham treated subjects. The presence of
a single study evaluating the impact of treating OSA on symptoms of panic disorder implies a high risk of publication bias;
further RCTs are required to determine the impact of treating
OSA in individuals with panic disorder.
Posttraumatic Stress Disorder: Four studies were identified concerning the treatment of OSA in subjects with PTSD
(Table 2; Table S13, Appendix 2).69–72 All 4 studies that had
a high RoB were retrospective analyses of subjects undergoing CPAP treatment. CPAP compliance was the primary
outcome for all studies, which was lower in individuals with
PTSD than controls. In El-Sohl, lack of CPAP adherence was
associated with increased baseline nightmare severity and less
baseline EDS.70 Krakow, Collen, and Gharaibeh found that
reduction in nightmare frequency was associated with CPAP
compliance.69,71,72
Two case reports concerning the treatment of OSA in PTSD
were also identified (Table 2).73,74 Youakim reported a case of
a 42-year-old male veteran with PTSD and severe OSA who
was treated with CPAP, resulting in control of OSA symptoms,
nightmare reduction, and improvement in PSTD symptoms.74
Yarlagadda reported a case study of a 35-year-old male with
DSM-IV PTSD and chronic pain treated with fluoxetine 20 mg/
day and lorazepam 0.5 mg as needed, resulting in OSA, weight
gain, and hypertension. CPAP treatment was initiated in combination with lorazepam and antihypertensives.73
The studies of the treatment of OSA in PTSD were all retrospective reviews. The primary outcome for 3 of 4 studies was
CPAP compliance. While these studies had the advantage of
being able to identify factors that determine CPAP compliance,
they are less effective than randomized, prospective studies at
examining the treatment impact on PSTD severity. The control groups of these studies were more clearly oriented around
CPAP compliance than PTSD symptom reduction. Gharaibeh
used non-compliant participants as controls, whereas El-Sohl
and Collen employed a control group of individuals with OSA
without PTSD. The Krakow, El-Sohl, and Gharaibeh studies
also employed comparison to CPAP non-compliant participants
who were unaware of their compliance scores to examine baseline and follow-up symptom severity, which helped control for
the placebo effect to an extent. Prospective, controlled RCTs
with PTSD severity scales as outcome measures are required
to determine the impact of treating OSA on PTSD symptoms.

two disorders, MDD and PTSD, in which the quantity of reports
was higher, although the RoB for these studies was still moderate-high for all clinical populations. Despite the selection bias
identified for the studied populations with MDD and PTSD, it
appears that there is an elevated prevalence of OSA in these disorders. The median prevalence of OSA in MDD in eight clinical
populations was 48.1% (range: 0% to 66%), which is substantially higher than the general population. In the populationbased samples, the range was 7.4% to 44%; however, the 7.4%
prevalence for OSA in MDD is higher than the 3.3% prevalence
of OSA in the total study population. The median prevalence
of OSA in PTSD was 42.7% in seven clinic-based populations
(range: 1.3% to 83%). Both population-based studies also identified an elevated prevalence of OSA in PSTD (range: 46.4% to
50%). In contrast, four clinical reports on the prevalence of OSA
in BD have a median prevalence of 19.8%, which is within the
range of the general population, despite a similarly wide range
of prevalence of 2.9% to 66%. Due to the high RoB for these
studies, future prevalence studies will be required to confirm
the findings in MDD and PTSD and to begin to evaluate the
prevalence of OSA in other psychiatric diagnoses.
The second goal of this review was to identify and evaluate
interventions for OSA in individuals with psychiatric disorders.
The systematic review found reports on the use of CPAP, UPPP,
adenotonsillectomy, and armodafinil alone and in conjunction
with psychopharmaceuticals in psychiatric populations. These
studies were predominantly case studies, single assignment
trials, and retrospective chart reviews with high RoB. The only
RCT included was for the use of armodafinil in subjects with
MDD. CPAP therapy had positive outcomes in all populations
tested, except for BD. A series of case studies suggests that
CPAP may be linked to the development of manic episodes in
patients with BD, so these patients should be observed carefully in the first months of treatment. In MDD, single assignment trials of CPAP were associated with improved symptom
severity and decreased EDS. In subjects with PTSD, CPAP
reduced nightmare frequency and PTSD symptoms; however, PTSD was also a predictive factor for CPAP non-compliance. UPPP conducted in unmedicated subjects with MDD
decreased hypersomnia by 92% and reduced current depression to 10% from 34%. The use of armodafinil in participants
with a current major depressive episode in conjunction with an
antidepressant resulted in improvement in subjective, but not
objective symptoms of EDS. However, many of these results
were obtained in studies without placebo or sham controls, so
these conclusions are preliminary and indicate a need for further study. Due to the scarcity of studies evaluating the treatment of OSA in individuals and the high RoB for the included
studies, RCTs are required to assess the efficacy of OSA treatment in individuals with psychiatric disorders.

DISCUSSION
Summary of Evidence

Limitations

The first goal of this systematic review was to determine if
there are elevated levels of OSA in individuals with psychiatric
disorders. The prevalence of OSA in the general population is
24% for men and 9% for women, using a definition of AHI ≥ 5
without EDS.1,2 Overall, there were insufficient reports on the
prevalence of OSA in schizophrenia and other psychotic disorders, mood disorders, and anxiety disorders to draw conclusions
about the prevalence of OSA in psychiatric patients. There were
Journal of Clinical Sleep Medicine, Vol. 11, No. 2, 2015

Overall, the systematic review reveals that the relationship
between OSA and psychiatric disorders is an area requiring
substantial further study. There are few studies examining
OSA in individuals with clinically diagnosed psychiatric disorders. The available data are largely concentrated in patient
populations with MDD or PTSD. This may be related to (1)
the clinical observation that patients with OSA show increased
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depressive symptoms and (2) the interest of the military in the
effective treatment of PTSD from a multisystem perspective.
The primary limitation of this systematic review is the
overall quality of evidence. The RoB assessment was high for
78.9% of the included prevalence studies. In addition, there is
substantial heterogeneity in study design for both prevalence
and intervention studies with a lack of global agreement on
the OSA and psychiatric diagnostic criteria. The retrospective
studies for both prevalence and intervention are also further
complicated by the use of lifetime psychiatric disorder diagnoses (as opposed to current episodes), which confounds the
relationship between the severity of the psychiatric disorder
and the presence and severity of OSA.
It is also apparent that many studies are conducted in samples of convenience, such as sleep clinic patient referrals with
psychiatric diagnoses, psychiatric inpatients, or members of
the military. While these studies present important preliminary
findings, they are highly subject to publication bias. Populations
selected from sleep clinic referrals for PSG due to reported
symptoms of OSA are also subject to a selection bias. A sample
that presents with clinical signs of OSA is significantly more
predisposed to a high rate of OSA than a random sample of
individuals with psychiatric disorders. Psychiatric inpatients
have a selection bias due to their clinical status. Inpatients
may have more severe psychiatric disorders than community
dwelling individuals, which may increase the levels of obesity
due to more expansive drug regimens that may contribute to
metabolic syndrome. In addition, inpatients are likely to have a
lower level of activity than community dwelling subjects due to
the restrictions placed on their movements, which in turn could
contribute to obesity and increased risk of developing OSA.
The military population is primarily, if not exclusively, composed of male combat veterans and is the subject of the largest
population-based study included in this review. This population
may also have a different presentation of psychiatric disorders
than the general population, as psychological testing a is a routine part of joining the armed forces and military personnel are
exposed to different acute stressors than the general population.
The intervention studies are also subject to an overall high
RoB. The scarcity of data is problematic, as the major interventions for OSA such as CPAP, adenotonsillectomy, UPPP, and
wake-promoting drugs have not been studied in many psychiatric disorders. It is also problematic that many of these studies are single-assignment, open-label studies or retrospective
chart reviews. In the absence of adequate sham or active controls, participant and personnel blinding, and randomization,
it is difficult to determine if the improvement in psychiatric
symptom severity is an effect of the treatment or the result of
the placebo effect. Prospective, randomized controlled trials
will be required to improve the quality of evidence to support
the conclusions of these studies across all diagnoses.

necessarily indicate the absence of elevated levels of OSA in
these populations, but points to the necessity of further study.
A number of factors may play a role in the association between psychiatric disorders such as MDD and PTSD with
OSA (Figure 2). Oxidative and nitrosative stress, inflammation, and neurotransmitter imbalances play a role in all of the
included psychiatric disorders.75 This underlying molecular
dysregulation manifests as psychiatric symptoms, but it also
alters the neurobiological and endocrine function of these individuals, leading to the association of psychiatric disorders
with obesity, diabetes, and cardiovascular disease. Psychiatric
disorders have independent associations with obesity, metabolic syndrome, cardiovascular disease, and smoking, which
are all independent predictors of OSA.75–82 Central nervous
system (CNS) alterations in psychiatric disorders may also
lead to an increased risk of OSA, as sympathetic hyperactivity and hyperarousal states and resultant sleep fragmentation
may lead to upper airway instability, which may contribute to
subsequent OSA.83,84 In chronic psychiatric disorders such as
MDD and PTSD, it can be hypothesized that the severity of
the dysfunction in each of these areas leads to slow and incremental increases in CNS activation and endocrine dysregulation. Eventually, as all of these changes affect homeostasis, the
individual responds with further biological dysregulation, and
the feed-forward process continues with a probable end result
of metabolic syndrome, severe CNS dysregulation, and OSA.
The addition of psychiatric medication to correct the underlying molecular dysfunction and treat psychiatric symptoms
may alleviate the issues in the CNS, but contributes to the further development of metabolic syndrome and possibly upper
airway resistance as a result of extrapyramidal side effects,
which in turn continue to stimulate the proposed feed-forward
mechanisms leading to OSA.85–87 The association between obesity and psychiatric medication is well known,79,82,85,87,88 but the
direct effects of these drugs on the upper airway and breathing
during sleep are important factors. The tranquilizing effects
of sleep medications and benzodiazepines may have direct
effects on breathing during sleep which results in airway obstruction.89–93 Atypical antipsychotics, a group of medications
that are generally associated with fewer extrapyramidal side
effects, have been associated with an increased AHI in a crosssection of psychiatric patients, even when compared to patients
with similar BMI and neck circumference taking benzodiazepines, opioids, and sleeping agents.86 This result points to an
obesity independent effect of antipsychotics on OSA, possibly
due to their extrapyramidal side effects.
The feed-forward mechanism proposed for the development
of OSA (Figure 2) is a general hypothesis for the co-evolution
of OSA in psychiatric disorders, and not all aspects will be present in every patient. Psychiatric disorders are associated with
different types of neurobiological dysregulation that manifests
as specific secondary effects. For example, HPA axis dysregulation is a prominent feature of PTSD and MDD, both of which
appear to be associated with increased OSA. Anxiety disorders are associated with increased activity in the amygdala and
insula, but only PTSD is correlated with additional decreased
activity in the hippocampus, anterior cingulate cortex, and
medial prefrontal cortex, which leads to a reduced ability to
regulate the fear response.94 This contributes to sympathetic

CONCLUSIONS
The results of this systematic review point to limited evidence that OSA may be elevated in MDD and PTSD, with
insufficient evidence to draw conclusions on any other DSMIV-TR diagnoses for schizophrenia and other psychotic disorders, mood disorders, and anxiety disorders. This does not
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Journal of Clinical Sleep Medicine, Vol. 11, No. 2, 2015

MA Gupta and FC Simpson

Downloaded from jcsm.aasm.org by 207.136.114.76 on June 22, 2022. For personal use only. No other uses without permission.
Copyright 2022 American Academy of Sleep Medicine. All rights reserved.

Figure 2—Proposed feed-forward pathway for the development of symptoms of upper airway instability and OSA from
biological, psychiatric, and metabolic dysregulation.

Each symptom cluster is an independent entry point to the cycle. If left untreated, the presence of a risk factor increases the likelihood of the synergistic
development of more symptoms from each cluster, resulting in OSA. The bolded arrows denote the most salient associations in the model.

hyperarousal during both sleep and wakefulness, and the hypervigilant states observed in PTSD and resultant sleep fragmentation, which may lead to instability of upper airways
during sleep and upper airway resistance. In MDD, HPA axis
dysregulation is a result of increased corticotrophin releasing
hormone sensitivity, glucocorticoid resistance, and increased
cortisol levels.93,95 The downstream effects of this dysregulation are more likely to manifest as metabolic syndrome. These
are both examples of disorder specific HPA axis dysregulation
that manifest differently, but which have feed-forward effects
into sleep symptoms eventually manifesting as OSA.
The most clinically significant finding of this review is the
importance of recognizing and treating OSA when it occurs
in an individual with a psychiatric disorder. OSA results in
chronic intermittent hypoxia and arousals from sleep leading
Journal of Clinical Sleep Medicine, Vol. 11, No. 2, 2015

to sleep fragmentation, which has been shown to cause neurocognitive and mood deterioration in otherwise mentally robust individuals.96,97 In psychiatric populations who already
experience dysregulation of mood and possible neurocognitive
deficits, it is likely that the same degree of hypoxic insult and
sleep fragmentation may result in greater decompensation of
the psychiatric disorder. Case study reports and clinical trials
both suggest that the treatment of OSA with CPAP can help to
reduce the need for psychopharmaceuticals, and to help clarify which symptoms originate from the primary psychiatric
illness. Polysomnographic evaluation of treatment-resistant
psychiatric patients (for example, MDD and PTSD) can be
considered an excellent tool to determine if a sleep disorder is
complicating a refractory psychiatric disorder. In cases where
OSA is present, a combination of CPAP and pharmaceutical
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treatment may result in greater therapeutic efficacy than traditional psychopharmacology alone.
Future studies on prevalence, incidence, and interventions
need to be conducted to better ascertain the relationship between psychiatric disorder and OSA. There is a pressing need
for additional population-based studies of OSA in community
dwelling individuals with psychiatric disorders to allow for
better comparison to the general population. Clinicians who
wish to initiate trials of interventions for OSA in psychiatric
population should consider sham or active comparator RCTs
to better understand the impact of specific treatments in psychiatric populations. In light of the heterogeneity in study
populations, participants in these studies should be diagnosed
with OSA following the newly introduced ICSD-3 criteria, and
the use of standard sleep outcomes should be encouraged to
ensure that inter-study comparisons are possible in the future.
Psychiatric diagnoses should continue to be made using a clinical interview following current DSM criteria, and validated
psychiatric severity scales should be included as outcome
measures, even where the primary trial goal is ascertaining
compliance. This review reveals that there is a substantial opportunity to develop research projects to better understand the
relationship between OSA and psychiatric disorders.
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APPENDICIES
Appendix 1: Included and Excluded Studies
Table S1—PubMed search strategy.
DSM-IV-TR Category

Schizophrenia and
Other Psychotic
Disorders

Mood Disorders

ICD-9-CM Code
295

(sleep apnea OR upper airway resistance syndrome) AND (Schizophrenia OR schizophreniform disorder
OR schizoaffective disorder)

297

(sleep apnea OR upper airway resistance syndrome) AND (paranoia OR delusional disorder OR
paraphrenia OR shared psychotic disorder OR paranoid state)

298

(sleep apnea OR upper airway resistance syndrome) AND (nonorganic psychoses OR reactive confusion
OR acute paranoid reaction OR psychogenic paranoid psychosis OR psychosis)

296

(sleep apnea OR upper airway resistance syndrome) AND (mood disorder OR bipolar disorder OR manic
disorder OR major depressive disorder OR atypical manic disorder OR atypical depressive disorder OR
episodic mood disorder)

300

(sleep apnea OR upper airway resistance syndrome) AND (anxiety OR panic disorder OR agoraphobia
OR generalized anxiety disorder OR dissociative disorder OR conversion disorder OR factitious disorder
OR hysteria OR dissociative amnesia OR dissociative fugue OR dissociative identity disorder OR phobia
OR social phobia OR acrophobia OR claustrophobia OR obsessive-compulsive disorder OR dysthymic
disorder OR neurasthenia OR depersonalization disorder OR hypochondriasis OR somatization OR
somatoform disorder OR psychoneurosis)

308

(sleep apnea OR upper airway resistance syndrome) AND (acute stress OR catastrophic stress OR
combat fatigue OR gross stress reaction)

309

(sleep apnea OR upper airway resistance syndrome) AND (adjustment reaction OR prolonged depressive
reaction OR separation anxiety disorder OR posttraumatic stress disorder)

Anxiety Disorders
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Psychiatric Classification Evaluated by
Scale or Self-Report (44)
Aikens 1999
Aikens 1999b
Asghari 2012
Bakim 2012
Balsevicius 2012
Beutler 1981
Borak 1996
Calhoun 2011
Carney 2011
Castro 2013
Chai-Coetzer 2013
DeZee 2005
DeZee 2006
Doherty 2003
Douglas 2013
Ekici 2013
Farney 2004
George 1987
Grunstein 1996
Hayashida 2007
Jacobsen 2013
Jennum 1994

Klonoff 1987
Krakow 2007
Lau 2010
Lehto 2012
Machado 2006
Moroni 2011
Nambu 1999
Profant 2003
Ramos Platon 1992
Rey de Castro 2013
Reyes-Zúñiga 2012
Sanchez 2001
Schwartz 2003
Skinner 2013
Stepnowsky 2002
Tihacek-Sojic 2012
Uloza 2009
Uloza 2010
Valipour 2007
Vgontzas 2011
Wallace 2013
Yang 2011

OSA Reported
without PSG (21)

Data not
Extractable (9)

Cheng 2013
Einvik 2011
Einvik 2013
Gupta 2014
Krakow 2002
McCall 2009
Mellman 1997
Motomura 2004
Nasr 2010
Naismith 2004
Naismith 2005
Ohayon 2003
Soreca 2011
Soreca 2012
Spoormaker 2005
Takahashi 1998
Turvey 2008
Vukin 2009
Waters 2013
Wheaton 2012
Whooley 2012

Babson 2013
Balan 1998
Best 2013
Breslau 2004
Krakow 2000b
Krakow 2001
Krakow 2001b
Krakow 2004
Reynolds 1982

175G

OSA and
Psychiatric
Diagnosis
both Required
for Inclusion
(3)
Edlund 1991
Sforza 2002
Yesavage 2010

Incidence
Study (1)
Chen 2013

Psychiatric
Disorder of
Interest not
Included in
this Review
(2)

Review or
Editorial (2)

Berrettini 1980
Munoz 1998

Kierlin 2009
Moldofsky 1999
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Appendix 2: Systematic Review Results
Table S5—Studies of the prevalence of OSA in individuals with schizophrenia and psychotic disorders.24,25,30,31

Ancoli-Israel 1999
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Participants
with
Schizophrenia
and Psychotic
Disorders

Population-Based
Studies

Clinic-Based Studies

Study
n

52

Levine 2001
143

Winkelman 2001
93

Sharafkhaneh 2005

46

138,371

M/F

35/17

104/39

50/43

37/9

Overall sample was
90.2% male

OSA %

48%

0.7%

3.2%

47.8%

4.52%

Referrals for sleep
disturbances on
psychiatric inpatients

Inpatient records
of Veteran’s Health
Administration from
1992–2001

Study Population

Participants from a
larger study of latelife psychosis

Age (mean ± SD)

59.6 ± 8.9

41 ± 13

41 ± 10

35.3 ± 8.4

–

BMI (mean ± SD)

28.5 ± 7.4

–

–

31.5 ± 8.2

–

Psychiatric Drug Use

85%

–

–

100%

–

Schizophrenia Criteria

DSM-III-R
schizophrenia or
schizoaffective
disorder

DSM-IV
schizophrenia

DSM-IV
schizoaffective
disorder

DSM-III-R
schizophrenia

ICD-9-CM: 295, 297,
298

OSA Criteria

RDI ≥ 10

RDI > 10

ICD-9-CM: 780.51,
780.53, 780.57

Consecutive psychiatric patients at state
hospital

Overnight PSG and oxyhemoglobin
desaturation

Overall Risk of Bias
High
High
High
Low
Assessment
rd
(–), not reported; BMI, body mass index; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders, 3 Edition Revised; DSM-IV, Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; PSG,
polysomnography; RDI, respiratory disturbance index.
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Table S6—Prevalence of OSA in individuals with bipolar disorders (BD).24,25,30,32–34

Winkelman 2001

Levine 2001

Hattori 2009

Kelly 2013

Sharafkhaneh 2005

n

92

66

13

482

71,362

M/F

30/62

39/27

Overall sample was
75% male

193/289

Overall sample was
90.2% male

OSA %

18.5%

2.9%

69%

21%

6.94%

Study Population

Referrals for sleep
disturbances on
psychiatric inpatients

Consecutive
psychiatric patients at
state hospital

Mood disorder
patients with HAM-D
≥ 10 and clinical
signs of OSA

Consecutive patients
at a depression and
bipolar disorder clinic
from October 2005 to
December 2008

Inpatient records
of Veteran’s Health
Administration from
1992–2001

Age (mean ± SD)

38.0 ± 15.0

42 ± 12

–

M: 43.53 ± 15.10
W: 45.37 ± 14.17

–

BMI (mean ± SD)

27.9 ± 7.6

–

–

26.7 ± 5.51

–

Psychiatric Drug Use

21.7%

–

–

–

–

BD Criteria

DSM-III-R BD-I and
BD-II

DSM-IV bipolar
disorder

DSM-IV bipolar
affective disorder,
HAM-D ≥10

BD-I, BD-II, BD-NOS

ICD-9-CM: 296.1,
296.4–296.8

OSA Criteria

RDI >10

Overnight PSG and
oxyhemoglobin
desaturation

AHI ≥5

AHI ≥15 or AHI ≥5
with EDS

ICD-9-CM:
780.51, 780.53,
780.57

BD
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Population-Based
Studies

Clinic-Based Studies

Study

Overall Risk of Bias
High
High
High
High
Low
Assessment
(–), not reported; AHI, apnea hypopnea index; BMI, body mass index; BD, bipolar disorder; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders,
3rd edition revised; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; EDS, excessive daytime sleepiness; HAM-D, Hamilton Rating
Scale for Depression; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; RDI, respiratory disturbance index.

Table S7—Studies of the prevalence of OSA in individuals with depressive disorders (MDD).24–26,30,32,35–39
Clinic-Based Studies
Study

Winkelman 2001

Levine 2001

Deldin 2006

Carney 2006

Population-Based Studies

Hattori 2009

Ong 2009

Summers 2010

Mysliwiec 2013

Hrubos-Strom
2012

Sharafkhaneh
2005

n

176

43

19

53

19

51

60

164

36

358,817

M/F

90/86

28/15

4/15

28/25

Overall sample
was 75% male

22/29

–

Overall sample
was 93.2% male

Overall sample
was 55.5% male

Overall sample
was 90.2% male

OSA %

12%

0%

53%

66%

53%

39%

46.7%

49.4%

44%

7.4%

Study Population

Referrals
for sleep
disturbances
on psychiatric
inpatients

Consecutive
psychiatric
patients at state
hospital

Participants recruited
from a larger study
on depression and
memory.

Subjects with
coronary heart
disease and MDD

Mood disorder
patients with
HAM-D ≥10 and
clinical signs
of OSA

Participants
from a RCT with
comorbid MDD
and insomnia

Subjects from
a tertiary mood
disorders clinic

Subjects with
diagnostic PSG
at a military
medical facility

Participants from
a populationbased survey
at high risk for
OSA based on
the BQ

Inpatient
records of
Veteran’s Health
Administration
from 1992–2001

Age (mean ± SD)

39.9 ± 6.6

41 ± 13

37.37 ± 11.52

53.8 ± 9.0

–

52.42 ± 9.82

–

–

–

–

BMI (mean ± SD)

27.0 ± 8.6

–

26.13 ± 7.40

30.1 ± 6.8

–

30.26 ± 9.07

–

–

–

–

Psychiatric Drug Use

Neuroleptics:
10.8%

–

Antidepressants: 37%
Sedative hypnotics: 16%

Excluded

–

Excluded

–

–

–

–

DSM-IV Major
Depressive
Disorder

DSM-IV-TR
MDD and ≥14
on the HAM-D
(also required
to have DSM-IV
insomnia)

Treatment
resistant
depression,
HAM-D > 18

EMR problem
list diagnosis of
depression

SCID-I for DSMIV MDD

ICD-9-CM: 296.2,
296.3, 296.9, 311

MDD

MDD Criteria

DSM-III-R MDD

DSM-IV MDD

SCID-I for DSM-IV MDD

Depression
Interview and
Structured
Hamilton (DISH)
for the DSM-IV
MDD criteria
and HAM-D for
severity.

OSA Criteria

RDI >10

Overnight
PSG and
oxyhemoglobin
desaturation

RDI > 5 major events
per hour

AHI ≥ 5 events
per hour

AHI ≥ 5

AHI ≥ 15

RDI >10

ICSD-2 OSA ,
AHI >5

AHI ≥ 5

ICD-9-CM
780.51, 780.53,
780.57

Overall Risk of Bias
Assessment

High

High

High

High

High

High

High

Moderate

Moderate

Low

(–) not reported; AHI, apnea hypopnea index; BMI, body mass index; BQ, Berlin questionnaire; CBT, cognitive behavioral therapy; CHD, coronary heart disease; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition revised;
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; EMR, electronic medical records; HAM-D, Hamilton Rating Scale for Depression; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification;
ICSD-2, International Classification of Sleep Disorders, 2nd edition; RDI, respiratory disturbance index; RCT, randomized controlled trial; SCID-I, Structured Clinical Interview for the DSM-IV axis I disorders.
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Table S8—Prevalence of OSA in individuals with anxiety disorders.25,26,39
Clinic-Based
Studies

Study

Population-Based Studies

Mysliwiec 2013
Anxiety Disorder
Diagnosis

Anxiety

Sharafkhaneh 2005

Pooled Anxiety

Pooled Anxiety

Panic Disorder
17

2

n

122

316,060

M/F

Overall sample was
93.2% male

Overall sample was
90.2% male

OSA %

Hrubos-Strom 2012
Agoraphobia w/o
panic disorder

Social phobia

Obsessive
compulsive disorder

Generalized anxiety
disorder

Current anxiety

13

5

14

43

57.1%

58.1%

Overall sample was 55.5% male

47.5%

6.4%

Study Population

Subjects with
diagnostic PSG at
a military medical
facility

Inpatient records
of Veteran’s Health
Administration from
1992–2001

58.8%

100%

53.8%

40%

Age (mean ± SD)

–

–

–

–

–

–

–

BMI (mean ± SD)

–

–

–

–

–

–

–

Diagnostic Criteria

EMR Problem List
excludes PTSD

ICD-9-CM: 300,
308, 309, 306

OSA Criteria

ICSD-2 OSA ,
AHI >5

ICD-9-CM: 780.51,
780.53, 780.57

AHI ≥ 5

Overall Risk of Bias
Assessment

Moderate

Low

Moderate

Participants from a population-based survey at high risk for OSA based on the BQ
–
–
SCID-I for DSM-IV
Includes PTSD

SCID-I for DSM-IV
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(–), not reported; AHI, apnea hypopnea index; BMI, body mass index; BQ, Berlin questionnaire; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; EMR, electronic medical records; ICD-9-CM,
International Classification of Diseases, Ninth Revision, Clinical Modification; ICSD-2, International Classification of Sleep Disorders, 2nd edition; RDI, respiratory disturbance index; SCID-I, Structured Clinical Interview
for the DSM-IV axis I disorders.

Table S9—Prevalence of OSA in individuals with PTSD.24–26,39–44
Clinic Based-Studies
Study Identifier

Population-Based Studies

Winkelman
2001

Krakow
2006

Kinoshita
2012

Yesavage
2012

Mysliwiec
2013

Mysliwiec
2013b

van Liempt
2011

Sharafkhaneh
2005

HrubosStrom 2012

n

76

89

120

105

96

39

20

31,186

16

M/F

9/67

11/78

120/0

105/0

Overall
sample was
93.2% male

Overall
sample was
97.3% male

20/0

Overall sample
was 90.2%
male

Overall
sample was
55.5% male

OSA %

0.7%

13.5%

83%

69%

42.7%

69%

29%

46.40%

50%

Study Population

Referrals
for sleep
disturbances
on
psychiatric
inpatients

Crime
victims selfreferred for
insomnia or
nightmares

Communitydwelling
male
veterans age
55 years or
older with
PSTD

Communitydwelling
male
veterans age
55 years or
older with
PSTD

Subjects
with
diagnostic
PSG at
a military
medical
facility

Military
personnel
deployed
within 18
months
presenting
for sleep
evaluation

Male
veterans
with PTSD
from
outpatient
Military
Mental
Healthcare
clinic

Inpatient
records of
Veteran’s
Health
Administration
from
1992–2001

Participants
from a
populationbased
survey at
high risk for
OSA based
on the BQ

Age (mean ± SD)

32.4 ± 9.1

40.36 ± 12.3

61.3 ± 4.0

59.9 ± 3.1

–

–

40.75 ± 8.45

–

–

BMI (mean ± SD)

27.5 ± 7.9

26.97 ± 6.41

30.7 ± 5.6

31.1 ± 6.10

–

–

27.86 ± 4.86

–

–

Psychiatric Drugs

14.3%

–

–

–

–

–

–

–

–

PTSD Criteria

DSM-III-R
PTSD

DSM-IV
criteria
for PTSD,
PSDS ≥ 11

CAPS
current or
lifetime
score ≥ 40

CAPS
current or
lifetime
score ≥ 40

EMR
problem list
diagnosis of
PTSD

PTSD
Checklist
Military
Version, with
a score of
≥ 50

SCID for
DSM-IV,
CAPS > 50,
two physician
consensus

ICD-9-CM:
309.81

SCID-I for
DSM-IV

OSA Criteria

RDI > 10

AASM
guidelines
for SDB

AHI ≥ 5

AHI > 10

ICSD-2
OSA,
AHI > 5

AHI > 5

AHI > 10

ICD-9-CM:
780.51,
780.53, 780.57

AHI ≥ 5

Overall Risk of
Bias Assessment

High

High

High

High

Moderate

High

High

Low

Moderate

PTSD

AASM, American Academy of Sleep Medicine; AHI, apnea hypopnea index; BQ, Berlin questionnaire; DSM-III-R, Diagnostics and Statistics Manual of Mental Disorders,
Third Edition, Revised; BQ, Berlin questionnaire; CAPS, Clinician Administered PTSD Scale; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical
Modification; SCID for DSM-IV, Structured Clinical Interview for the DSM-IV axis I disorders; PSDS, Posttraumatic Stress Diagnostic Scale; UARS, upper airway
resistance syndrome.
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Table S10—Case studies of interventions for individuals with schizophrenia and psychotic disorders and OSA.45–54
Age

Sex

Diagnosis

Psychiatric Symptoms

Initial Medications

OSA Symptoms

Treatment

Outcome

Lee 1989

30

M

atypical psychosis, mild grade
mental retardation

EDS, talking nonsense,
yelling and stripping in
public, drinking insecticide,
confusional behavior, loosening
of association, self-muttering,
inappropriate giggling, irrational
behaviors, paranoid delusions

obesity, temporal lobe
epilepsy (grand mal seizures),
obstructed oropharyngeal
space

phenytoin 300 mg/day,
carbamazepine 800 mg/day,
haloperidol 20 mg/day

AHI 10, SaO2 78%, No SWS

adenotonsillectomy

cessation of EDS and apneas,
no further need for neuroleptics

Bottlender 1999

60

M

delusional disorder, jealous
type (DSM-IV 297.1)

blunted affect, affective
rigidity, retarded, inhibited
and restricted thinking, lack
of drive, social withdrawal,
systematized, low dynamic
delusional thinking

parkinsonian syndrome

haloperidol 20 mg/day,
haloperidol-decanoate 3
mL i.m. 14 day interval,
chlorprothixene 80 mg/day,
theralene 10 drops/day

Unspecified

risperidone 6 mg/day,
monotherapy,CPAP

CPAP continued to improve
negative symptoms such as
lack of drive, general loss of
energy and affective blunting

Chiner 2001

52

M

episodic schizophrenia
with inter-episodic residual
symptoms, undifferentiated
type (DSM-IV 295.92)

social isolation, lack of
initiative, weight gain, EDS,
severe snoring

–

chlorpromazine

AHI 52, AI 36, ESS 19, SaO2
95%, Min SaO2 81%

CPAP at 8cm H2O

CPAP reduced EDS but
induced an acute psychotic
episode requiring hospital
admission

Dennis 2001

38

M

DSM-IV schizoaffective
disorder

aggression, physically
assaultive behavior, auditory
hallucinations, delusions,
impaired memory

obesity

quetiapine 800 mg/day,
lithium carbonate 900 mg/day,
valproic acid 1500 mg/day

MinSaO2: 51%, AHI 168

CPAP, continued psychiatric
medication

improved memory, cessation
of aggressive and assaultive
behavior

Wirshing 2002
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Presenting Medical
Comorbidities

First Author

45

F

DSM-IV schizophrenia

rapid weight gain, voracious
appetite

obesity, hypertriglyceridemia,
glucose Intolerance

clozapine 300 mg/day

AHI 36, Min SaO2 87%

CPAP, clozapine 300 mg/day

improvement in sleep difficulty,
EDS and OSA

50

M

schizophrenia

weight gain, difficulty sleeping,
frequent unrestful daytime
naps, snoring and apnea

obesity, diabetes

risperidone 6 mg/day

Min SaO2 71%

CPAP, risperidone 6 mg/day

improvement in OSA symptoms

Boufidis 2003

36

M

schizophrenia

BPRS 64, BDI-II 35, insomnia,
fatigue, EDS, nightmare,
choking sensation

obesity

risperidone 16 mg,
lormetazepam 4 mg,
zolpidem 20 mg,
diazepam 3 0 mg,
clorazepate dipotassium 15 mg,
biperiden 2 mg

RDI 88, SaO2 86%, ESS 14

nCPAP, weight loss diet,
risperidone 6 mg, zolpidem 10
mg, clorazepate dipotassium
60 mg, biperiden 4 mg

at 8-month follow-up the
patient had lost 14 kg, with
significant improvement in
clinical symptoms, BPRS 38,
BDI 19, ESS 9

Sugishita 2003

44

M

ICD-10 schizophrenia

depressive mood, fatigue,
EDS, mild brain atrophy

weight 72 kg, BMI 24.3

Velasco-Rey
2012

51

M

depressive disorder with
psychotic symptoms

mutism, listless, motionless,
self-referential and prejudicialtype delusions, depressive
symptoms, delusions
of reference, auditory
hallucinations, two suicide
attempts, snoring, EDS

Troy 2013

39

M

schizophrenia

snoring, EDS

Seeman 2014

55

F

psychosis

fatigue, EDS

AHI 43.6

CPAP reducing AHI to 2.3

PNSS improved to 20 from 34,
GAF improved to 38 from 31

venlafaxine 150 mg/day
ketazolam 30 mg/day
risperidone 4 mg/day

AHI 32

CPAP at 9 cm H2O

one month after CPAP the
patient was asymptomatic, so
medication was withdrawn;
complete remission persisted
at one year follow-up

obesity 137 kg, type II diabetes
mellitus, blood pressure:
119/64 mmHg

oral hypoglycemics
Insulin

RDI 108, Min SaO2 59%,
ESS 19

CPAP at 20 cm H2O, clozapine
425 mg, diabetic-integrated
care

ESS = 7, improvement in
memory, positive symptoms of
schizophrenia less distressing
but constant

BMI 28.32, blood pressure:
140/90 mmHg

fluphenazine 4 mg/day
metoprolol 25 mg BID

AHI 30

CPAP, weight loss program

CPAP resolved EDS, weight
loss, decrease in blood
pressure

(–), not reported; AHI, apnea hypopnea index; AI, arousal index; BDI, Beck Depression Inventory; BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; CPAP, continuous positive airway pressure; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition;
EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; ICD-10, International Classification of Diseases, 10th Revision; Min SaO2, minimum oxygen saturation; SaO2, oxygen saturation; PNSS, Positive and Negative Syndrome Scale; RDI, respiratory disturbance
index.

Table S11—Case reports of mania in OSA.55–58
Symptoms Prior to
OSA Diagnosis

Presenting Medical
Comorbidities

Medications at
Admission

OSA
Symptoms

M

EDS, drowsiness,
speech impairment,
anhedonia, anxiety,
loss of appetite,
suicidal ideation

right hemiplegia,
motor deficiency

clorazepate 20 mg,
venlafaxine 300 mg,
trazodone 50 mg

64

M

tired, sleepy, without
energy

type 2 diabetes
mellitus

Bastiampillai
2010

40

F

Bipolar affective
disorder diagnosed
at 16, manic and
psychotic symptoms

Aggarwal
2013

51

M

60

M

First Author

Age

Sex

Hilleret 2001

50

Berge 2008

Outcome and Long
Term Therapies

Treatment

Manifestation of Mania

AHI 44,
MinSaO2 59%

CPAP

15 days on CPAP:
quarrelsome and
uninhibited

CPAP continued with
concomitant valproate

metformin 850 mg
every 8 hours

AHI 47,
MinSaO2 73%

CPAP, 9 h at 20 cm
continuous pressure,
venlafaxine

1 month CPAP: motor
hyperactivity, euphoria,
excessive socialization,
verbal aggression,
verbosity, weight gain

risperidone 9 mg/day,
valproate 1200 mg/
day, weight loss of 1 kg
in 2 weeks following
admission

obesity

olanzapine 5 mg

type II
respiratory
failure, obesity

failed numerous drug
therapies, continual
respiratory failure,
12 ECT treatments
initiated, BiPAP
between treatments

on admission: manic and
psychotic symptoms

CPAP, lithium 450 mg
BID, olanzapine 5 mg/
morning

BD-I since 16,
GAD, depressed
mood, anhedonia,
decreased
concentration,
isolation, fatigue,
anxiety, difficulty
maintaining sleep

ulcerative colitis,
hypertension,
borderline diabetes

lithium 900 mg,
gabapentin 600 mg

AHI 94.6,
MinSaO2 85%

CPAP 7 cm H2O

3 weeks CPAP: euphoria,
physical aggression,
motor hyperactivity,
racing thoughts,
decreased sleep,
pressured speech

lithium 1200 mg,
gabapentin 900 mg,
risperidone 3 mg

BD-I disorder,
snoring, restless
sleep

hypercholesterolemia,
benign prostatic
hyperplasia,
postcolon resection
due to colon cancer

divalproate 1500 mg,
quetiapine 400 mg,
lamotrigine 200 mg

AHI 64.7,
MinSaO2 88%

CPAP 11 cm H2O

2–3 weeks CPAP:
pressured speech,
euphoric mood,
psychomotor agitation,
grandiose delusions

olanzapine 25 mg/
day, lithium 600 mg/
day, divalproate 1500
mg, quetiapine 400 mg,
continued CPAP

(–), not reported; AHI, apnea hypopnea index; BD-I, bipolar disorder type I; BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; CPAP, continuous positive airway pressure; EDS, excessive daytime
sleepiness; Min SaO2, minimum oxygen saturation; SaO2, oxygen saturation.
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Table S12—Interventions for depressive disorders and OSA.60–67
Authors

Dahlöf 2000

Mackinger 2004

Habukawa 2010

El-Sherbini 2011

Krystal 2011

Study Design

Prospective, SingleAssignment, Open-Label

Prospective, SingleAssignment, Open Label

Prospective, SingleAssignment, Open-Label

Prospective, SingleAssignment, Open-Label

Prospective, randomized,
double-blind, parallelgroup, placebo controlled

Number of Patients

MDD: 12
Dysthymia: 5
Depression NOS: 1
Control: 35

MDD History: 18
Control: 18

17

MDD: 11
Control: 26

Armodafinil: 125
Placebo: 124

M/F

Depression: 18/0
Control: 35/0

MDD: 7/11
Control: 10/9

15/2

24/13

Armodafinil: 57/68
Placebo: 58/66

Study Population

Consecutive patients
diagnosed with OSA at a
sleep clinic

Patients at a sleep
disorders center

Patients with MDD
referred to sleep clinic
for suspected OSA on
stable antidepressants or
benzodiazepines

Participants with suspected
OSA evaluated for MDD

Outpatients with a stable
CPAP and antidepressant
regimen

Age (mean ± SD)

50 ± 9

MDD: 47.3 ± 8.6
Control: 49.0 ± 7.8

47.6 ± 7.5

–

Armodafinil: 49.5 ± 10.3
Placebo: 49.5 ± 9.7

BMI (mean ± SD)

–

–

28.2 ± 4.0

–

Armodafinil: 37.3 ± 7.9
Placebo: 36.2 ± 7.8

Psychiatric drugs

Excluded

–

100%

–

100%

SCID-I for DSM-IV

DSM-IV-TR MDD or
dysthymic disorder, HAM-D
< 17, stable SSRI or SNRI
for ≥ 8 weeks at study
baseline

SCID-I for DSM-IV, codes
296.xx and 300.4

DSM-IV MDD, receiving
anti-depressants at a
stable dose for ≥ 2 months

MDD Criteria

SCID for DSM-III-R current
major depressive episode

OSA Criteria

DI ≥ 5 or minimum 30
desaturations during 7 hour
sleep study

RDI unspecified

AHI ≥ 10

AHI > 5

ICSD OSA, stable CPAP
regimen for ≥ 4 weeks
resulting in AHI ≤ 10 at
baseline, CPAP use ≥ 4
h per night, ESS ≥ 10,
CGI-C ≥ 4

Intervention

Uvulopalatopharyngoplasty

nCPAP

CPAP

CPAP

Armodafinil titrated to
200 mg or placebo daily

Treatment Duration

N/A, follow up 6 months
postsurgery

6–9 weeks

2 months

2 months

12 weeks

Outcome Measures

PSG, SCID, GAF, CPRS,
DST

RDI, BDI, AM

PSG, BDI, HAM-D, ESS

HAM-D, ESS, SCID-I

CGI-C, MWT, ESS, PSG,
QIDS-SR-16, TEAEs
Minimal CGI-C
improvement was greater
with armodafinil (68%) than
placebo (53%) (p = 0.003).
MWT showed no significant
changes. ESS score
showed a greater decrease
for armodafinil (−6.3) than
placebo (−4.8)

Moderate

Relevant Results

Hypersomnia decreased
from 98% to 6%
postoperatively. The rate
of current depression
decreased from 34%
to 10% and GAF score
increased.

CPAP reduced the nightly
RDI of participants in both
groups. Pre and post BDI
scores were significantly
reduced for the MDD
group. Group × time
interactions did not show a
difference between change
in MDD and Con.

CPAP reduced depression
on both the BDI and
HAM-D scales. The
improvement in depression
correlated with improved
ESS scores.

HAM-D scores decreased
significantly for all
subjects post-CPAP.
SCID-I diagnosed MDD
resolved for 6 subjects; the
remaining 5 were classified
with mild MDD. Total ESS
score decreased from 11.6
± 8.6 to 5.1 ± 3.1. HAM-D
scores were correlated
with ESS scores (r = 0.7,
p = 0.000).

Overall Risk of Bias
Assessment

High

High

High

High

AHI, apnea hypopnea index; AM, autobiographical memory; BDI, Beck Depression Inventory; CPAP, continuous positive airway pressure; CGI-C, Clinical Global Impression of
Change; CPRS, Comprehensive Psychopathological Rating Scale; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition revised; DSM-IV, Diagnostic
and Statistical Manual of Mental Disorders, 4th edition; DST, dexamethasone suppression test; ESS, Epworth Sleepiness Scale; GAF, Global Assessment of Functioning Scale;
HAM-D, Hamilton Rating Scale Depression; MWT, maintenance of wakefulness test; NOS, not otherwise specified; PSG, polysomnography; QIDS-SR-16, Quick Inventory of
Depressive Symptomatology Self Report; SCID, Structured Clinical Interview for DSM-III-R; SCID-I, Structured Clinical Interview for DSM-IV axis I disorders; SNRI, serotonin–
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TEAE, treatment emergent adverse events.
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Table S13—Interventions for PTSD and OSA.69–72
Study ID

Krakow 2000

El-Sohl 2010

Collen 2012

Gharaibeh 2013
Retrospective Review

Study Design

Retrospective Survey

Retrospective case-control study

Retrospective casecontrol study

Number of Patients

Tx: 14 (10 OSA, 4 UARS)
NoTx: 9 (6 OSA, 3 UARS)

OSA+PTSD: 148
OSA-PTSD: 148

OSA+PTSD: 45
OSA-PTSD: 45

43

M/F

–

OSA+PTSD: 148/0
OSA-PTSD: 148/0

OSA+PTSD: 38/7
OSA-PTSD: 38/7

–

Study Population

Veterans with chronic
nightmares

Male veterans with PTSD referred to
a sleep clinic between January 2005
and June 2009

Adult patients at military
sleep clinic between
January and October
2009

Patients with OSA and
PTSD treated at a VHA
sleep clinic between May
2011 and May 2012

Age (mean ± SD)

Tx: 43.8 ± 14.1
NoTx: 50.8 ± 14.9

OSA+PTSD: 59.7 ± 7.9
OSA-PTSD: 61.5 ± 8.3

OSA+PTSD: 38.6 ± 9.2
OSA-PTSD: 37.0 ± 11.2

–

BMI (mean ± SD)

Tx: 35.8 ± 10.2
NoTx: 31.8 ± 6.0

OSA+PTSD: 35.4 ± 6.9
OSA-PTSD: 34.9 ± 6.3

OSA+PTSD: 27.8 ± 4.4
OSA-PTSD: 26.9 ± 9.2

–

Sedatives:
OSA+PTSD: 82.9%
OSA-PTSD: 13.3%

–
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Tx

Antidepressants: 57.1%
Benzodiazepines: 35.7%
Antipsychotics: 21.4%
NoTx Antidepressants: 77.7%
Benzodiazepines: 55.5%
Antipsychotics: 0%

Psychiatric drugs

Excluded

PTSD Criteria

Weekly nightmares for
> 6 months, psychosocial
impairment from dreams

DSM-IV PTSD

Structured clinical
interview for DSM-IV-TR
PTSD and PCL-M > 50

Diagnostic code for PTSD

OSA Criteria

OSA: AHI > 10
UARS: airflow irregularities
below hypopnea threshold,
excessive EEG microarousals, intermittent or
frequent snoring culminating
in an EEG micro-arousal

AHI ≥ 5
Mild: 5 ≤ to < 15
Moderate: 15 ≤ to <30
Severe: > 30

AASM criteria

Diagnostic code for OSA

Intervention

CPAP

CPAP

CPAP

CPAP

Treatment Duration

≈ 21 months

30 days

4–6 weeks

–

Outcome Measures

Change in nightmares and
PTSD symptoms quantified
by survey

Compliance (> 4 h/night, > 70% of
days)

Compliance (regular use
> 4 h/night, > 70% of
nights)

Compliance (> 4 h/night),
nightmare frequency

Participants with PTSD
had lower overall
compliance with CPAP
on all measures of
compliance. Regular use
was 25.2% compared
to 58.3% on non-PTSD
controls.

Nightmare frequency was
reduced in both classes
of OSA, and predicted by
CPAP compliance.

High

High

Relevant Results

Overall Risk of Bias
Assessment

Compliance was 41% in OSA+PTSD
and 70% in OSA-PTSD
PAP non-adherent veterans had a
higher prevalence of nightmares than
More individuals in the CPAP
adherent subjects (56% vs. 28%).
compliant group showed
They were also less sleepy at baseline
improvement in nightmare
(ESS: 12.1 ± 5.9 vs. 14.4 ± 5.3)
and PTSD symptoms.
Psychiatric Drug Use after CPAP
Participants in the NoTx
Tx	Antidepressants: 28.6%
group were more likely to
	Benzodiazepines: 28.6%
stay the same or worsen.
	Antipsychotics: 0%
NoTx	Antidepressants: 44.4%
	Benzodiazepines: 66.6%
	Antipsychotics: 0%
High

High

(–), not reported; AASM, American Academy of Sleep Medicine; AHI, apnea hypopnea index; CPAP, continuous positive airway pressure; DSM-IV, Diagnostic
and Statistical Manual of Mental Disorders, 4th edition; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision; ESS,
Epworth Sleepiness Scale; NoTx, untreated; PTSD, posttraumatic stress disorder; Tx, treatment; UARS, upper airway resistance syndrome; VHA, Veteran’s
Health Administration.
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Appendix 3: Risk of Bias
Section A: Prevalence Studies
A ncoli -I srael 1999
Prospective
No

2. Was the sampling frame a true or close representation of the target population?

No

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

4. Was the likelihood of non-response bias minimal?

Yes

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g,.
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

Overall Risk: Moderate

Carney 2006

External Validity

Criteria

Internal Validity
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Internal Validity

External Validity

Criteria
1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

2. Was the sampling frame a true or close representation of the target population?

No

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

4. Was the likelihood of non-response bias minimal?

No

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g,.
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

Overall Risk: High
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Single Location

134/503 agreed to participate. Black patients
were more likely to participate than white,
but no other significant differences between
participants and non-participants.
PSG & DISH (DSM-IV)

Review Article
D eldin 2006

Internal Validity

External Validity

Criteria

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

2. Was the sampling frame a true or close representation of the target population?

No

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

Recruited by flyers

4. Was the likelihood of non-response bias minimal?

No

Not mentioned

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

SCID DSM-IV & PSG

H attori 2009

External Validity

Criteria

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

2. Was the sampling frame a true or close representation of the target population?

No

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

4. Was the likelihood of non-response bias minimal?

Internal Validity
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Overall Risk: High

Unclear

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

Overall Risk: High
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H rubos -S trom 2012

Internal Validity

Prospective
Yes

Randomly drawn from National Population
Register

2. Was the sampling frame a true or close representation of the target population?

Yes

Randomly drawn from National Population
Register

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

Yes

Randomly selected

4. Was the likelihood of non-response bias minimal?

Yes

55.7% response to initial survey. At next
randomization stage (participants from BQ
high risk), a significantly higher proportion of
participants were categorised as BQ somnolent
when compared with BQ high-risk responders
who did NOT participate. No differences
with respect to age, sex, snoring, obesity, or
hypertension.

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

SCID DSM-IV & PSG

Overall Risk: Moderate
K elly 2013

External Validity

Criteria

Internal Validity
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External Validity

Criteria
1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

Retrospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

2. Was the sampling frame a true or close representation of the target population?

No

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

Consecutive

4. Was the likelihood of non-response bias minimal?

N/A

Chart review

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

Overall Risk: High
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Diagnosed & PSG

Review Article
K inoshita 2012

Internal Validity

External Validity

Criteria

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

Yes

San Francisco Bay Area veterans

2. Was the sampling frame a true or close representation of the target population?

Yes

168 veterans who responded to ads or were
referred

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

Recruited by advertisements

4. Was the likelihood of non-response bias minimal?

No

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

All assessments were conducted prospectively

6. Was an acceptable case definition used in the study?

Yes

CAPS & PSG

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

K rakow 2006

External Validity

Criteria

Internal Validity
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Overall Risk: High

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

2. Was the sampling frame a true or close representation of the target population?

No

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

4. Was the likelihood of non-response bias minimal?

No

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

Convenience samples

PTSD Diagnostic Scale & PSG/Autoset

Some participants received AutoSet home
monitoring instead of PSG.

Overall Risk: High
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Levine 2001

Internal Validity

External Validity

Criteria

Retrospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?
2. Was the sampling frame a true or close representation of the target population?
3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No
Unclear
No

Single hospital
Psychiatric patients from referrals for greater
Pittsburgh
Consecutive patients

4. Was the likelihood of non-response bias minimal?

N/A

Chart review

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

Medical records

6. Was an acceptable case definition used in the study?

Yes

DSM-IV criteria and PSG

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

DSM-IV & PSG (from records)

8. Was the same mode of data collection used for all subjects?

Yes

Medical records

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

M ysliwiec 2013

External Validity

Criteria

Internal Validity
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Overall Risk: High

Retrospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

Only military personnel were eligible.

2. Was the sampling frame a true or close representation of the target population?

Yes

All military personnel who underwent sleep
medicine evaluations 2011–2012 were eligible.

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

Recruited by advertisements, 160/1416
volunteered

4. Was the likelihood of non-response bias minimal?

N/A

Only 11.3% of potentially eligible military
personnel were referred for screening.

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

No

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

Overall Risk: Moderate
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PSG & PTSD checklist

6 completed split-night PSG

Review Article
M ysliwiec 2013 b
Retrospective
No

2. Was the sampling frame a true or close representation of the target population?

Yes

Major military medical treatment facility

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

ALL diagnostic PSGs

4. Was the likelihood of non-response bias minimal?

No

Chart review

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

No

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

Diagnosis from electronic medical records
problem list & PSG

Patients who met criteria for severe OSA
underwent split-night PSG

Overall Risk: High
O ng 2009

External Validity

Criteria

Internal Validity
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Internal Validity

External Validity

Criteria
1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

2. Was the sampling frame a true or close representation of the target population?

No

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

Recruited by flyers

4. Was the likelihood of non-response bias minimal?

No

Not mentioned

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

DSM-IV-TR & PSG

Overall Risk: High
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S harafkhaneh 2005

Internal Validity

External Validity

Criteria

Retrospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

The VA serves current and former soldiers and
military families.

2. Was the sampling frame a true or close representation of the target population?

Yes

The entire VA EMR system was used over the
time period assessed.

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

Yes

The entire VA EMR system was used over the
time period assessed.

4. Was the likelihood of non-response bias minimal?

N/A

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

Data was retrieved from EMR

6. Was an acceptable case definition used in the study?

Yes

ICD-9-CM coding

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

EMR

S ummers 2010

External Validity

Criteria

Internal Validity
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Overall Risk: Low

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

2. Was the sampling frame a true or close representation of the target population?

Yes

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

4. Was the likelihood of non-response bias minimal?

No

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

Overall Risk: High
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Not mentioned
Diagnosed TRD & PSG

Review Article
van Liempt 2013

Internal Validity

External Validity

Criteria

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

2. Was the sampling frame a true or close representation of the target population?

No

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

Recruited through outpatient clinic, controls
recruited through ads

4. Was the likelihood of non-response bias minimal?

No

Not mentioned

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

SCID-DSM-IV & PSG

Winkelman 2001

External Validity

Criteria

Internal Validity
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Overall Risk: High

Retrospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?

No

Single center

2. Was the sampling frame a true or close representation of the target population?

No

Single center

3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

No

Consecutive referrals

4. Was the likelihood of non-response bias minimal?

N/A

Chart review

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

DSM-III-R and PSG (RDI >10)

Overall Risk: High
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Yesavage 2012
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Internal Validity

External Validity

Criteria

Prospective

1. Was the study’s target population a close representation of the national population
in relation to relevant variables, e.g., age, sex, occupation?
2. Was the sampling frame a true or close representation of the target population?
3. Was some form of random selection used to select the sample, OR, was a census
undertaken?

Yes
Unclear
No

4. Was the likelihood of non-response bias minimal?

No

5. Were data collected directly from the subjects (as opposed to a proxy)?

Yes

6. Was an acceptable case definition used in the study?

Yes

7. Was the study instrument that measured the parameter of interest (e.g.,
prevalence of low back pain) shown to have reliability and validity (if necessary)?

Yes

8. Was the same mode of data collection used for all subjects?

Yes

9. Was the length of the shortest prevalence period for the parameter of interest
appropriate?

Yes

10. Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?

Yes

San Francisco Bay Area
“expected demographic make-up of Vietnamera veterans living in this region”
Recruited through media advertisement &
local veteran agencies
All assessments were conducted
prospectively
CAPS & PSG

Overall Risk: High

Section B: Interventions
C ollen 2012
Study design

Observational, case-controlled study

Random sequence generation

N/A

Single allocation

Allocation concealment

N/A

Single allocation

Blinding of participants and personnel

Unclear

Blinding of outcome assessment

High

Participants were blind to compliance data

Incomplete outcome data

Low

No records were excluded from the analysis

Selective reporting

Low

Other sources of bias

Unclear

Dahlof 2000
Study design

Single-assignment, open-label

Random sequence generation

N/A

Single allocation

Allocation concealment

N/A

Single allocation

Blinding of participants and personnel

High

None

Blinding of outcome assessment

High

None

Incomplete outcome data

Low

Seven excluded. One patient was excluded due to alcohol abuse, two patients
due to current treatment with psychotropic drugs, and three patients due to known
psychiatric illness.

Selective reporting

Low

Other sources of bias

High
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Review Article
El-S herbini 2011
Study design

Single-assignment, open-label

Random sequence generation

N/A

Single allocation

Allocation concealment

N/A

Single allocation

Blinding of participants and personnel

High

The psychiatrist was blinded to the severity of sleep disturbance while conducting
psychiatric assessment

Blinding of outcome assessment

Unclear

Incomplete outcome data

Low

Selective reporting

Low

Other sources of bias

Unclear

Seven excluded. Two refused to contribute in the study, two had a previous
psychiatric diagnosis, two refused treatment with CPAP, and one was not compliant
with CPAP.
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El-S ohl 2010
Study design

Single-assignment, case-control, open-label

Random sequence generation

N/A

Single allocation

Allocation concealment

N/A

Single allocation

Blinding of participants and personnel

High

None

Blinding of outcome assessment

Low

Participants were blind to the assessment of CPAP compliance

Incomplete outcome data

Low

At 1-month follow-up, 6 PTSD veterans and 1 control failed to return to clinic

Selective reporting

Low

Other sources of bias

Unclear

G haraibeh 2013
Study design

Single-assignment, case-control, open-label

Random sequence generation

N/A

Single allocation

Allocation concealment

N/A

Single allocation

Blinding of participants and personnel

High

None

Blinding of outcome assessment

Low

Participants were blind to the assessment of CPAP compliance

Incomplete outcome data

Unclear

Selective reporting

Low

Other sources of bias

Unclear

H abukawa 2010
Study design

Single-assignment, open-label

Random sequence generation

N/A

Single allocation
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Allocation concealment

N/A

Blinding of participants and personnel

Unclear

Blinding of outcome assessment

Unclear

“respiratory events were scored…by a technician blind to the aim of the study and the
subject’s identity”

Incomplete outcome data

Low

Three excluded for AHI <10

Selective reporting

Low

Other sources of bias

Unclear

Single allocation
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K rystal 2011
Study design

Randomized, double-blind, parallel-group study

Random sequence generation

Unclear

Randomization stratified by center. Methodology not described.

Allocation concealment

Unclear

Unclear

Blinding of participants and personnel

Unclear

States double-blind

Blinding of outcome assessment

Unclear

States double-blind

Incomplete outcome data

Low

47 excluded. 14 consent withdrawn, 2 lost to follow-up, 31 other reasons.

Selective reporting

Low

Other sources of bias

Unclear

M ackinger 2004
Study design

Single-assignment, parallel group study

Random sequence generation

N/A

Single allocation

Allocation concealment

N/A

Single allocation

Blinding of participants and personnel

Unclear

Blinding of outcome assessment

Unclear

Incomplete outcome data

Low

3 excluded: 1 acute schizophrenic psychosis, 2 history of BP

Selective reporting

High

Missing post treatment total BDI scores

Other sources of bias

Unclear

Takaesu 2012
Study design

Randomized, crossover study

Random sequence generation

Unclear

States randomization

Allocation concealment

Low

Use of sham CPAP and CPAP

Blinding of participants and personnel

Unclear

Blinding of outcome assessment

Unclear

Incomplete outcome data

Low

Selective reporting

Low

Other sources of bias

Unclear
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7 excluded due to CPAP discomfort
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